NYSE: DVADavita Inc Stock
$144.57-1.41 (-0.97%)
Updated Jul 30, 2025
DVA Price
$144.57
Fair Value Price
N/A
Market Cap
$10.92B
52 Week Low
$131.76
52 Week High
$179.60
P/E
14x
P/B
-40.86x
P/S
0.94x
PEG
1.36x
Dividend Yield
N/A
Revenue
$12.97B
Earnings
$859.61M
Gross Margin
32.5%
Operating Margin
12.6%
Profit Margin
6.6%
Debt to Equity
-57.88
Operating Cash Flow
$2B
Beta
0.56
Next Earnings
Aug 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DVA Overview
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the U.S and internationally. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. Seventy percent of the company's revenues come from Medicare and other government-based health insurance programs. The company was founded in 1979 and is based in Denver, CO.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DVA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
DVA
Ranked#22 of 41
Ranked#22 of 41
Be the first to know about important DVA news, forecast changes, insider trades & much more!
DVA News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DVA ($144.57) is trading above its intrinsic value of $95.86, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DVA is good value based on its earnings relative to its share price (14x), compared to the US market average (32.18x)
P/E vs Market Valuation
DVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DVA due diligence checks available for Premium users.
Valuation
DVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
14x
Industry
15.49x
Market
32.18x
DVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-40.86x
Industry
4.32x
DVA price to earnings growth (PEG)
For valuing profitable companies with growth potential
DVA is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DVA's financial health
Profit margin
Revenue
$3.2B
Net Income
$162.9M
Profit Margin
5.1%
DVA's Earnings (EBIT) of $1.63B... subscribe to Premium to read more.
Interest Coverage Financials
DVA's profit margin (6.6%) has... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.1B
Liabilities
$15.5B
Debt to equity
-57.88
DVA's short-term assets ($3.64B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DVA's long-term liabilities ($12.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$180.0M
Investing
-$162.1M
Financing
-$382.5M
DVA's operating cash flow ($2.34B)... subscribe to Premium to read more.
Debt Coverage Financials
DVA vs Medical Care Facility Stocks
Davita Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.